Ignite Creation Date:
2024-05-06 @ 12:30 PM
Last Modification Date:
2024-10-26 @ 12:59 PM
Study NCT ID:
NCT03773302
Status:
TERMINATED
Last Update Posted:
2024-05-08
First Post:
2018-12-10
Brief Title:
Phase 3 Study of BGJ398 Oral Infigratinib in First Line Cholangiocarcinoma With FGFR2 Gene FusionsTranslocations
Sponsor:
Organization:
QED Therapeutics Inc